After more than 20 years without human testing of therapeutic interventions, Lassa fever research has reached a critical inflection point. Two early-phase clinical trials published in Nature Medicine mark the first simultaneous advancement in both vaccine and treatment candidates for a virus that infects an estimated 100,000 to 300,000 people annually across West Africa.
The trials represent a watershed moment for a disease that has languished in the shadows of global health priorities despite its significant burden. With case fatality rates ranging from 1% to 29% depending on viral lineage, Lassa fever has long remained one of medicine’s most neglected threats. Recent advances in platform technologies and decades of foundational animal research have finally enabled the transition to human-phase testing, signaling renewed institutional and scientific commitment to addressing this persistent viral hemorrhagic fever.
These developments offer hope for populations across West Africa who have awaited effective countermeasures for generations.
Read the full article on GMJ Newsroom.
Was this article helpful?
